1 Result: Ipsen
Momentum Surge: Elafibranor's PBC Trial Data Boosts Genfit
June 30th, 2023
Ipsen S.A. (OTCMKTS: IPSEY) and Genfit S.A. (Nasdaq: GNFT) have announced positive results from the ELATIVE Phase III trial evaluating elafibranor as a treatment for patients with primary biliary cholangitis (PBC), a rare cholestatic liver disease, w. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login